deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02730169

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Sponsor: Mereo BioPharma

Conditions Hypogonadotropic Hypogonadism
Interventions BGS649 Placebo
Updated 16 times since 2017 Last updated: Aug 26, 2022 Started: May 12, 2016 Primary completion: Feb 15, 2018 Completion: May 19, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hypogonadotropic Hypogonadism, this trial is completed. The trial is conducted by Mereo BioPharma and has accumulated 16 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2020 · 25 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Sep 2022 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Nov 2018 — Dec 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  7. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  8. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  9. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  10. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mereo BioPharma
Data source: Mereo BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Anaheim, United States , Ancona, Italy , Baltimore, United States , Barnsley, United Kingdom , Birmingham, United States , Bradenton, United States , Carlsbad, United States , Chandler, United States , Charlotte, United States and 53 more locations